Documents
Application Sponsors
ANDA 210503 | LAURUS LABS LTD | |
Marketing Status
None (Tentative Approval) | 001 |
None (Tentative Approval) | 002 |
Application Products
002 | TABLET;ORAL | 300MG | 0 | CANAGLIFLOZIN | CANAGLIFLOZIN |
FDA Submissions
UNKNOWN; | ORIG | 1 | TA | 2022-01-28 | STANDARD |
Submissions Property Types
CDER Filings
LAURUS LABS LTD
cder:Array
(
[0] => Array
(
[ApplNo] => 210503
[companyName] => LAURUS LABS LTD
[docInserts] => ["",""]
[products] => [{"drugName":"CANAGLIFLOZIN","activeIngredients":"CANAGLIFLOZIN","strength":"100MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"},{"drugName":"CANAGLIFLOZIN","activeIngredients":"CANAGLIFLOZIN","strength":"300MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"}]
[labels] =>
[originalApprovals] => [{"actionDate":"01\/28\/2022","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2022\\\/210503Orig1s000TA_ltr.pdf\"}]","notes":"> Label is not available on this site."}]
[supplements] =>
[actionDate] => 2022-01-28
)
)